FORM PTO-THAP U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	SERIAL NO.
1188-37 RCE/DIV	10/728,015
APPLICANT Minotti et al.	CONFIRMATION NO.
FILING DATE	GROUP
December 4, 2003	1623

U.S. PATENT DOCUMENTS

		U.S. F	ATENT DUCUMENT	3		
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
M	4,203,900	05/20/90	Kaiser		_	
	4,206,221	06/03/90	Miller et al.			
	4,303,439	12/01/81	Howe et al.			
	4,354,029	10/12/82	Kaiser et al.		-	
	4,360,678	11/23/82	Howe et al.			
·.	4,443,611	04/17/84	Kaiser	- Tarbana		
	4,543,414	09/24/85	Carson	٠.=		
-	4,743,700	05/10/88	Jamm et al.	1		•
	4,814,470	03/21/89	Colin et al.	1		
•	4,857,653	08/15/89	Colin et al.	-		
	4,876,399	10/24/89	Holton et al.			
	4,877,881	10/31/89	Belliotti et al.		-	
	4,924,002	05/08/90	Kostlan		~~	
	4,924,011	05/08/90	Denis et al.		-	
	4,924,012	05/08/90	Colin et al.	•	-	
an	4,942,184	07/17/90	Haugwitz et al.	-		

EXAMINER

allhone

DATE CONSIDERED

9/16/04

				ATTY. DOCKET NO. 1188-37 RCE/DIV			AL NO. 28,015	
61				APPLICAN Minotti et		CON	FIRMATION NO.	
MAR	0 8 2004	(Use several sheets	if necessary)		FILING DA		GRO 1623	
	ANEMARIA	4,960,790	10/02/90	Stella et al.		-		·
		5,015,744	05/14/91	Hotan			~	
		5,059,699	10/22/91	Kingston et	al.		_	
		5,128,478	07/07/92	Ito et al.			<u> </u>	
-	,	5,136,060	08/04/92	Holtan				
_		5,194,635.	03/16/93	Kingston et	al.			
	-	5,208,237	05/04/93	Hewawasan	n et al.		_	
		5,227,400	07/13/93	Holton et al.	•		_	
		5,243,045	09/07/93	Holton et al.	•			
		5,254,580	10/19/93	Chen				
-	*	5,264,591	11/23/93	Bombardelli	et al.			,
		5,272,171	12/21/93	Ueda et al.				
		5,278,324	01/11/94	Kingston et	al.			
		5,283,253	02/01/94	Holton et al.				
		5,296,506	03/22/94	Kingston				
	-	5,319,112	06/07/94	Kingston et.	al.	-		
		5,352,806	10/04/94	Gunawardan	a et al.			
	m-	5,399,726	03/21/95	Holton et al.			_	

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

DATE CONSIDERED

EXAMINER

0/16/014

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE SERIAL NO. ATTY. DOCKET NO. (Rev. 2-32) PATENT AND TRADEMARK OFFICE 1188-37 RCE/DIV 10/728,015 INFORMATION DISCLOSURE APPLICANT CONFIRMATION NO. STATEMENT BY APPLICANT Minotti et al. FILING DATE (Use several sheets if necessary) **GROUP** December 4, 2003 1623 5,420,337 05/30/95 Patel et al. 08/08/95 5,440,056 Klein et al. 5,449,790 09/12/95 Zheng et al. 5,468,769 11/21/95 -Klein et al. 5,476,954 12/19/95 Borzat et al. 5,556,878 09/17/96 Kelly et al. 5,580,997 12/02/96 Bouchard et al. 5,589,502 12/31/96 Tsujihara et al. 5,616,739 04/01/97 Mas et al. 5,618,952 04/08/97 Holton et al. 5,621,121 04/15/97 Cammercon et al. 5,635,531 06/03/97 Chen 5,637,732 06/10/97 Holton et al. 5,646,176 07/08/97 Golik et al. 5,670,658

EXAMINER

M

Lihand

5,677,470

5,710,287

5,721,268

09/23/97

10/14/97

01/20/98

02/24/98

DATE CONSIDERED

0/16/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

Bastart

Tsujihara et al.

Holton et al.

Holton et al.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE			ATTY. DOCKET NO. 1188-37 RCE/DIV			SERIAL NO. 10/728,015	
E JC100	INFORMATION DI STATEMENT BY			APPLICANT Minotti et a		CON	FIRMATION NO.
0 8 2004 B	(Use several sheets	if necessary)		FILING DA December		GRO 1623	
OEMBY.		Υ	1				
A TRADEUS	5,728,687	03/17/98	Bissery			_	
	5,728,725	03/17/98	Holton et al	•		<u>~</u>	
	5,760,252	06/02/98	Holton et al	•			
	5,767,296	06/16/98	Terasawa e	al.	,	_	
	5,773,461	06/30/98	Wittma et a	l	-	_	
	5,808,102	09/15/98	Poss et al.			_	
	5,840,931	11/24/98	Bouchard et	al.	. —	_	
	5,847,170	12/08/98	Bouchard et	al.			
	5,889,043	03/30/99	Bouchard et	al.		_	·
	5,908,835	06/01/99	Bissery				
	6,005,120	12/21/99	Holton et al.	***			
	6,020,507	02/01/00	Gibson			_	
	6,043,375	03/28/00	Borzat et al.			_	
	6,072,060	06/06/00	Suidell et al.				
	6,096,909	08/01/00	Ojima				
	6,100,411	08/08/00	Ojima		-	_	-118
	6,214,863	04/10/01	Bissery				
ah	6,239,167	05/29/01	Bissery		_		
EXAMINE	e dun	M I	DATE CONS	IDERED	9/16	lok	

FORM PTO-1 P EREV 2-32) MAR 1 8 2004

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PRO 2-32) PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	SERIAL NO.
1188-37 RCE/DIV	10/728,015
APPLICANT Minotti et al.	CONFIRMATION NO.
FILING DATE	GROUP
December 4, 2003	1623

M	6,248,908	06/01	Kant	•		
	6,340,701	01/02	Chari et al.			
aw	6,353,120	03/02	Kant		_	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANS	LATION NO
an	JP 55-145650	11/13/80	Japan				
	JP 61-005022	01/10/86	Japan				
	JP 61-51578	11/10/86	Japan	,		-11	
	JP 60-222416	11/07/85	Japan		-	_	
	ЭР61-115022	06/02/86	Japan		_		_
	JP 9208572A	08/12/97	Japan j			. Newster	
	WO 90/02738	03/22/90	PCT		1		
	WO 92/09589	06/11/92	РСТ)		
	WO 92/19765	11/12/92	РСТ		_		
	WO 94/07876	04/14/94	РСТ			-	
	WO 94/13655	06/23/94	РСТ		_		
m	WO 94/14787	07/07/94	PCT	_			

EX	Α	Λ	M	V	Ε	F
LiΛ	Л	·ΙV	ш	N	Ľ	I

dehare

DATE CONSIDERED

9/16/04

FORM PT Rev. 2-1

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	SERIAL NO.
1188-37 RCE/DIV	10/728,015
APPLICANT Minotti et al.	CONFIRMATION NO.
FILING DATE	GROUP
December 4, 2003	1623

	}					
WO 95/03265	02/02/95	PCT				
WO 96/00724	01/11/96	PCT		_		
WO 96/13495	05/09/96	PCT	-			
WO 96/14309	05/17/96	PCT	F	\		
WO 96/23779	08/08/96	РСТ		_		
WO 97/09979	03/20/97	PCT		(
WO 97/23472	07/03/97	PCT		-		
WO 97/32578	09/12/97	PCT				
WO 97/32869	09/12/97	PCT				
WO 98/01435	01/15/98	PCT		_		
WO 98/22451	05/28/98	PCT		v		_
WO 99/33462	07/08/99	PCT				
EP 0 359 516 B1	08/10/94	EPO	-			
EP 0 400 971 B1 & A3	07/29/98	EPO		_		
EP 0 428 376 B1	01/10/96	EPO		_		
EP 0 505 047 B1 & A1	04/24/96	EPO				
EP 0 537 905 B1 & A1	03/06/96	EPO			`	
EP 0 604 910 A1	07/06/04	EPO				
	WO 96/00724 WO 96/13495 WO 96/14309 WO 96/23779 WO 97/09979 WO 97/23472 WO 97/32578 WO 97/32869 WO 98/01435 WO 98/22451 WO 99/33462 EP 0 359 516 B1 EP 0 400 971 B1 & A3 EP 0 428 376 B1 EP 0 505 047 B1 & A1 EP 0 537 905 B1 & A1	WO 95/03265 02/02/95 WO 96/00724 01/11/96 WO 96/13495 05/09/96 WO 96/14309 05/17/96 WO 96/23779 08/08/96 WO 97/09979 03/20/97 WO 97/23472 07/03/97 WO 97/32578 09/12/97 WO 97/32869 09/12/97 WO 98/01435 01/15/98 WO 98/22451 05/28/98 WO 99/33462 07/08/99 EP 0 359 516 B1 08/10/94 EP 0 400 971 B1 & A3 07/29/98 EP 0 505 047 B1 & A1 04/24/96 EP 0 537 905 B1 & A1 03/06/96	WO 95/03265 02/02/95 PCT WO 96/00724 01/11/96 PCT WO 96/13495 05/09/96 PCT WO 96/14309 05/17/96 PCT WO 96/23779 08/08/96 PCT WO 97/09979 03/20/97 PCT WO 97/32578 09/12/97 PCT WO 97/32869 09/12/97 PCT WO 98/01435 01/15/98 PCT WO 98/22451 05/28/98 PCT WO 99/33462 07/08/99 PCT EP 0 359 516 B1 08/10/94 EPO EP 0 400 971 B1 8 A3 07/29/98 EPO EP 0 428 376 B1 01/10/96 EPO EP 0 555 047 B1 8 A1 04/24/96 EPO EP 0 537 905 B1 8 A1 03/06/96 EPO	WO 95/03265 02/02/95 PCT WO 96/00724 01/11/96 PCT WO 96/13495 05/09/96 PCT WO 96/14309 05/17/96 PCT WO 96/14309 05/17/96 PCT WO 96/23779 08/08/96 PCT WO 97/09979 03/20/97 PCT WO 97/23472 07/03/97 PCT WO 97/32578 09/12/97 PCT WO 97/32869 09/12/97 PCT WO 98/01435 01/15/98 PCT WO 98/22451 05/28/98 PCT WO 99/33462 07/08/99 PCT EP 0 400 971 B1 08/10/94 EPO EP 0 428 376 B1 01/10/96 EPO EP 0 505 047 B1 A1 04/24/96 EPO EP 0 537 905 B1 03/06/96 EPO —	WO 95/03265 02/02/95 PCT WO 96/00724 01/11/96 PCT WO 96/13495 05/09/96 PCT WO 96/13495 05/09/96 PCT WO 96/14309 05/17/96 PCT WO 96/23779 08/08/96 PCT WO 97/09979 03/20/97 PCT WO 97/23472 07/03/97 PCT WO 97/32578 09/12/97 PCT WO 97/32869 09/12/97 PCT WO 98/01435 01/15/98 PCT WO 98/22451 05/28/98 PCT WO 99/33462 07/08/99 PCT EP 0 359 516 B1 08/10/94 EPO EP 0 400 971 B1 & A3 07/29/98 EPO EP 0 505 047 B1 & A1 04/24/96 EPO EP 0 537 905 B1 03/06/96 EPO —	WO 95/03265 02/02/95 PCT WO 96/00724 01/11/96 PCT WO 96/13495 05/09/96 PCT WO 96/14309 05/17/96 PCT WO 96/23779 08/08/96 PCT WO 97/09979 03/20/97 PCT WO 97/23472 07/03/97 PCT WO 97/32578 09/12/97 PCT WO 97/32869 09/12/97 PCT WO 98/01435 01/15/98 PCT WO 98/22451 05/28/98 PCT WO 99/33462 07/08/99 PCT EP 0 400 971 B1 8 A3 07/29/98 EPO EP 0 505 047 B1 8 A1 04/24/96 EPO EPO EP 0 537 905 B1 8 A1 03/06/96 EPO EPO

EXAMINER

dicharl

DATE CONSIDERED

a/16/04

75 2-32)	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			ATTY. DOCKET NO. 1188-37 RCE/DIV			SERIAL NO. 10/728,015 CONFIRMATION NO	
0 8 2004 W				Minotti et al. FILING DATE GROU December 4, 2003 1623			GROUP 1623	
					Г			
<u> </u>	1,061,330	08/28/79	Canada		-	_		
	1,695,918	05/06/71	German	1				
an	2,919,891	12/04/80	German	l		_		
ari 	impaired li Oxford, Gr ECCO: Tax —Doctor's G www.pslgro DG Dispato —Advanced I retrieved fro	M.G., et al; P ver function; eat Britain; v col/doxorubi- uide, 'Online oup.com/dg/ ch - ECCO: I Breast Cance om the Intern	harmaco Europea vol. 34, n cin Impree!, 22 Se 13144a.h New Dru er; Docto net: www	kinetics an Journ o. 1; Jar oves Sur ptember atm; retr g Comb r's Guid w.pslgro	of anticand al of Cance nuary 1998 rvival in M 1999; retri ieved 2002 ination Enl e; 'Online! up.com/dg	cer ager; Per letastal leved i l-11-00 hances l; 19 S /12c4;	ents in patients vigamon Press; tic Breast Cance from the Interne 6. Treatment for eptember 1999; 52.htm.	er;
	pharmacoki 1999), page	s 14-19.	ninars in	Oncolog	gy, Vol. 26	, No. 3	3, Suppl. 9 (June	
	the interacti	on between	doxorubi	icin and	paclitaxel	patien	and in vitro study ts with breast (1997) pages 19	•
m	doxorubicin	In vitro active and cisplaticer Research	n on prin	nary cell	l cultures o	f hum	an breast cancer	rs.
EXAMINER	2 Allane	DATI	E CONS	IDEREL	9	16/0	4	
	R: Initial if citation cons							

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 1188-37 RCE/DIV	SERIAL NO. 10/728,015	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Minotti et al.	CONFIRMATION NO.	
(Use several sheets if necessary)	FILING DATE December 4, 2003	GROUP 1623	
Wahl et al. "Selective tumo		9	
conjugate CBR96-doxorub	oicin. Abstract: Int. J. Ca	ncer vol. 4 (15 Aug.	

EXAMINER

minare

DATE CONSIDERED

9/16/04